Last updated: January 6, 2021
Sponsor: Nada Yousef
Overall Status: Active - Recruiting
Phase
N/A
Condition
Dry Mouth
Nasopharyngeal Cancer
Saliva And Salivary Gland Dysfunction
Treatment
N/AClinical Study ID
NCT04700475
P.T.REC/012/002269
Ages 25-55 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age range between 25-55 years.
- All patients included in the study established HNC and will receive radiotherapyencompassing major salivary glands accompanied or not by surgery.
- All patients enrolled to the study will have their informed consent.
- Both genders will participate in the study.
- All the patients were examined medically by oncologist
Exclusion
Exclusion Criteria:
- Diabetes mellitus,
- Autoimmune diseases as sjorgen syndrome by established diagnosis criteria.
- Infectious diseases
- Collagen diseases, as were those with incipient tumors (stage T1 or T2) limited to thelarynx, as well as those with trismus (reduced mouth opening capacity) due to surgicalsequelae.
- xerostomic drugs (antiretroviral medications, antihistamines, anticholinergics,antihypertensives, decongestants, narcotic analgesics, tricyclic antidepressants)
Study Design
Total Participants: 60
Study Start date:
September 04, 2020
Estimated Completion Date:
February 28, 2021
Study Description
Connect with a study center
Cairo university
Giza,
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.